Press Releases
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Results in Arthritis & Rheumatology
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
